Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Wolfgang Hiddemann, Annette Hänel et al.|Blood|2006Cited by 465
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Eva Hoster et al.|The Lancet|2016Cited by 401
Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma NetworkEva Hoster, Michael Unterhalt, Wolfgang Hiddemann et al.|Journal of Clinical Oncology|2014Cited by 164
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II TrialSimone Ferrero, Alessandro Pastore, Christian W. Scholz et al.|Leukemia|2015Cited by 12
110 | HIGH PFS WITH LOW INFIELD RECURRENCES AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE NODAL FOLLICULAR LYMPHOMA: FINAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)Klaus Herfarth, M. Dreyling, Christian Schölz et al.|Hematological Oncology|2025Cited by 0